Overview
I am a clinical investigator in the Division of Hematologic Malignancies and Cellular Therapy in the Department of Medicine. I serve as Director of the Leukemia Program and Director of Phase I Development in Hematologic Malignancies. I am also the Chair of the SWOG Leukemia Committee. I am interested in the clinical development of novel therapies for acute myeloid leukemia, myelodysplastic syndromes, myeloproliferative neoplasms (such as chronic myeloid leukemia, polycythemia vera, essential thrombocythemia and myelofibrosis), and acute lymphoblastic leukemia. Specifically, I have been the Principal Investigator for small molecular inhibitors, antibody-drug conjugates and cytotoxic chemotherapy.
Office Hours
Office hours:
Monday, 8 a.m. to 12 p.m.
Tuesday, 8 a.m. to 5 p.m.
Wednesday, 8 a.m. to 12 p.m.
Friday, 1 p.m. to 5 p.m.
Current Appointments & Affiliations
Professor of Medicine
·
2023 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2018 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Whole Genome Sequencing Informed Patient Personalized Measurable Residual Disease Assays for Acute Myeloid Leukemia.
Conference medRxiv · January 26, 2026 Post-treatment measurable residual disease (MRD) in acute myeloid leukemia (AML) patients is associated with adverse clinical outcomes. Validated molecular methods for AML MRD are preferable to flow cytometry assays but are not available for all patients. ... Full text Link to item CitePrognostic impact of age and MDS-associated mutations in NPM1 -mutated AML.
Preprint · November 6, 2025 Full text Link to item CiteV-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML.
Journal Article Blood Neoplasia · November 2025 Preclinical data suggest CPX-351, approved for patients with newly diagnosed therapy-related acute myeloid leukemia (AML) or AML with myelodysplasia-related changes, may exhibit synergy with targeted agents, suggesting a rationale for combining targeted ag ... Full text Link to item CiteRecent Grants
Study of AZD3632 Monotherapy or in Combination with Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or other Genotypes Associated with HOX Overexpression.
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2025 - 2030An Open-label, Phase 1b Study of R289, an IRAK1/4 Inhibitor, in Patients with Lower-risk Myelodysplastic Syndromes (LR-MDS) Who are Relapsed/Refractory/Resistant to Prior Therapies.
Clinical TrialPrincipal Investigator · Awarded by Rigel Pharmaceuticals, Inc. · 2025 - 2030Studies to Assess Ziftomenib in Combination with Ven+Aza or 7+3 in Patients with Untreated NPM1-m or KMT2A-r AML
Clinical TrialPrincipal Investigator · Awarded by Kura Oncology, Inc. · 2025 - 2030View All Grants
Education, Training & Certifications
Stanford University, School of Medicine ·
1988
M.D.
Stanford University ·
1988
Ph.D.